首页> 外文期刊>The Journal of Immunology: Official Journal of the American Association of Immunologists >Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells.
【24h】

Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells.

机译:体内肿瘤细胞凋亡的诱导增加了肿瘤抗原的交叉呈递,交叉引发而不是交叉耐受宿主肿瘤特异性CD8T细胞。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Cross-presentation of cell-bound Ags from established, solid tumors to CD8 cells is efficient and likely to have a role in determining host response to tumor. A number of investigators have predicted that when tumor Ags are derived from apoptotic cells either no response, due to Ag sequestration, issue of whether this happens in vivo has never been addressed, we induced apoptosis of established hemagglutinin (HA)-transfected AB1 tumors in BALB/c mice using the apoptosis-inducing reagent gemcitabine. This shrank the tumor by approximately 80%. This induction of apoptosis increased cross-presentation of HA to CD8 cells yet neither gross deletion nor functional tolerance of HA-specific CD8 cells were observed, based on tetramer analysis, proliferation of specific CD8 T cells, and in vivo CTL activity. Interestingly, apoptosis primed the host for a strong antitumor response to a second, virus-generated HA-specific signal in that administration of an HA-expressing virus after gemcitabine administration markedly decreased tumor growth compared with viral administration without gemcitabine. Thus tumor cell apoptosis in vivo neither sequesters tumor Ags nor cross-tolerizes tumor-specific CD8 cells. This observation has fundamental consequences for the development of tumor immunotherapy protocols and for understanding T cell reactivity to tumors and the in vivo immune responses to apoptotic cells.
机译:从成熟的实体肿瘤到CD8细胞的细胞结合抗原的交叉展示是有效的,并且可能在确定宿主对肿瘤的反应中具有作用。许多研究人员已经预测,当肿瘤Ags从凋亡细胞衍生而来时,由于Ag的螯合而没有反应,这种情况是否在体内从未得到解决,我们诱导了已被血凝素(HA)转染的AB1肿瘤的凋亡。使用凋亡诱导剂吉西他滨的BALB / c小鼠。这使肿瘤缩小了约80%。基于四聚体分析,特异性CD8 T细胞的增殖和体内CTL活性,这种凋亡诱导增加了HA向CD8细胞的交叉呈递,但未观察到HA特异性CD8细胞的总体缺失或功能耐受。有趣的是,凋亡的引发使宿主对第二种病毒产生的HA特异性信号具有较强的抗肿瘤反应,与吉西他滨给药相比,吉西他滨给药后表达HA的表达病毒的给药显着降低了肿瘤的生长。因此,体内肿瘤细胞凋亡既不隔离肿瘤Ag,也不交叉耐受肿瘤特异性CD8细胞。该观察结果对于肿瘤免疫疗法方案的发展以及对于理解T细胞对肿瘤的反应性以及对凋亡细胞的体内免疫反应具有根本的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号